20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Indivior PLC Ordinary Shares (INDV) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in North Chesterfield, United States with about 827 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, INDV reported $1.2B in revenue and $210M in net income.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Interactive charts & full statements → Open the INDV valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.3B | $1.2B | $1.2B | $1.1B | $901M | $791M | $647M | $785M | $960M | $1.1B | $969M |
| Gross Profit | $1.1B | $993M | $957M | $919M | $750M | $664M | $550M | $645M | $825M | $1.0B | $858M |
| Gross Margin % | 83.9% | 80.2% | 80.6% | 84.1% | 83.2% | 83.9% | 85.0% | 82.2% | 86.0% | 89.3% | 88.6% |
| Operating Income (EBIT) | $518M | $265M | $32M | ($156M) | ($81M) | $213M | ($156M) | $178M | $317M | $423M | $338M |
| Operating Margin % | 38.9% | 21.4% | 2.7% | -14.3% | -9.0% | 26.9% | -24.1% | 22.7% | 33.0% | 36.9% | 34.9% |
| Net Income | $355M | $210M | $2M | ($129M) | ($44M) | $205M | ($148M) | $134M | $263M | $61M | $32M |
| Net Margin % | 26.7% | 17.0% | 0.2% | -11.8% | -4.9% | 25.9% | -22.9% | 17.1% | 27.4% | 5.3% | 3.3% |
| EBITDA | $432M | $304M | $84M | ($99M) | ($46M) | $238M | ($123M) | $230M | $310M | $437M | $149M |
| Earnings Per Share (EPS) | $2.78 | $1.64 | $0.02 | $-0.91 | $-0.32 | $1.33 | $-1.01 | $0.89 | $1.75 | $0.41 | $0.22 |
| Shares Outstanding (M) | 129M | 128M | 133M | 142M | 139M | 154M | 147M | 151M | 150M | 150M | 149M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $343M | $317M | $358M | $314M | $302M | $266M | $299M | $307M |
| Gross Profit | $294M | $277M | $294M | $252M | $250M | $222M | $276M | $238M |
| Gross Margin % | 85.7% | 87.4% | 82.1% | 80.2% | 82.8% | 83.5% | 92.3% | 77.5% |
| Operating Income (EBIT) | $160M | $137M | $122M | $99M | $72M | $66M | $96M | $4M |
| Operating Margin % | 46.7% | 43.2% | 34.1% | 31.5% | 23.8% | 24.8% | 32.1% | 1.3% |
| Net Income | $122M | $89M | $102M | $42M | $18M | $47M | $59M | $4M |
| Net Margin % | 35.6% | 28.1% | 28.5% | 13.4% | 6.0% | 17.7% | 19.7% | 1.3% |
| EBITDA | $162M | $124M | $92M | $54M | $82M | $76M | $106M | $22M |
| Earnings Per Share (EPS) | $0.95 | $0.69 | $0.82 | $0.33 | $0.15 | $0.38 | $0.46 | $0.03 |
| Shares Outstanding (M) | 129M | 129M | 125M | 129M | 124M | 124M | 128M | 134M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($40M) | ($27M) | $36M | ($300M) | ($4M) | $353M | ($193M) | $151M | $303M | $295M | $407M |
| Capital Expenditures (CapEx) | $71M | $67M | $31M | $53M | $5M | $34M | $4M | $7M | $41M | $43M | $35M |
| Free Cash Flow (FCF) | ($111M) | ($94M) | $5M | ($353M) | ($9M) | $319M | ($197M) | $144M | $262M | $252M | $372M |
| FCF Margin % | -8.3% | -7.6% | 0.4% | -32.3% | -1.0% | 40.3% | -30.4% | 18.3% | 27.3% | 21.9% | 38.4% |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | $69M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $229M | ($9M) | ($221M) | ($39M) | $158M | $75M | ($5M) | $2M |
| Capital Expenditures (CapEx) | $7M | $20M | $24M | $20M | $18M | $5M | $16M | $7M |
| Free Cash Flow (FCF) | $222M | ($29M) | ($245M) | ($59M) | $140M | $70M | ($21M) | ($5M) |
| FCF Margin % | 64.7% | -9.2% | -68.4% | -18.8% | 46.4% | 26.3% | -7.0% | -1.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B | $1.2B | $1.3B | $1.8B | $1.8B | $1.8B | $1.5B | $1.7B | $1.5B | $1.4B | $1.2B |
| Cash & Cash Equivalents | $222M | $195M | $319M | $316M | $778M | $1.1B | $858M | $1.1B | $924M | $863M | $692M |
| Total Liabilities | $1.4B | $1.3B | $1.7B | $2.0B | $1.7B | $1.6B | $1.4B | $1.4B | $1.5B | $1.6B | $1.5B |
| Total Debt (Short + Long-Term) | $496M | $329M | $343M | $248M | $248M | $250M | $242M | $242M | $4M | $5M | $101M |
| Total Shareholders' Equity | ($208M) | ($98M) | ($348M) | ($191M) | $51M | $203M | $82M | $209M | $66M | ($203M) | ($295M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INDV viewer.
About TickerBase · Data methodology & sources · Privacy · Terms